Results 121 to 130 of about 36,363 (277)

In This Issue [PDF]

, 1993
Video institucional donde presenta la situación actual de la Universidad Militar Nueva Granada, conociendo su misión, programas académicos e ...
Emanuel, Janet Rettig
core   +1 more source

Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa

British Journal of Dermatology, 2019
Linked Comment: https://doi.org/10.1111/bjd.18377.
C. Has, L. Liu, M. Bolling, A. Charlesworth, M. Hachem, M. Escámez, I. Fuentes, S. Büchel, R. Hiremagalore, G. Pohla-Gubo, P. Akker, K. Wertheim-Tysarowska, G. Zambruno   +12 more
semanticscholar   +1 more source

Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US

The Journal of Dermatology, Volume 53, Issue 5, Page 758-773, May 2026.
ABSTRACT Vitiligo is a chronic autoimmune depigmenting disease characterized by loss of pigment in the skin, hair, or both. As treatment options evolve, particularly with the emergence of oral Janus kinase inhibitors and dual Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor, it is essential to assess ...
Kennedy Cook, Nada M. Elbuluk, Roni Adiri, Alexandre Lejeune, Thomas Edwards, Milena A. Gianfrancesco, Scott P. Kelly, Tatjana Lukic, Edward Nagy, Samantha K. Kurosky, Lynne Napatalung, Iltefat Hamzavi   +11 more
wiley   +1 more source

Real‐World Experience With Oleogel‐S10 for Wounds in Epidermolysis Bullosa

JEADV Clinical Practice
Background Oleogel‐S10 is the first approved drug for the treatment of wounds in patients with junctional and dystrophic epidermolysis bullosa. Results from the clinical trials, early access programme and open‐label study are available, showing good ...
Miodrag Davidovic, Stella Gewert, Cristina Has   +2 more
doaj   +1 more source

BMC Research Notes / Urine is a novel source of autologous mesenchymal stem cells for patients with epidermolysis bullosa [PDF]

, 2015
Background: Regenerative medicine is strictly dependent on stem cells as a source for a high diversity of somatic cells. However, the isolation of such from individuals suffering from severe genetic skin blistering diseases like epidermolysis bullosa (EB)
Bauer, Johann W., Buric, Ivana, Grillari, Johannes, Grillari-Voglauer, Regina, Jug, Bogdan, Kantner, Viktoria, Reynoso, Rita, Schosserer, Markus, Wally, Verena, Weilner, Sylvia   +9 more
core   +1 more source

Phenotypic Spectrum of Epidermolysis Bullosa: The Paradigm of Syndromic versus Non-Syndromic Skin Fragility Disorders.

Journal of Investigative Dermatology, 2019
The heritable forms of epidermolysis bullosa (EB), a phenotypically heterogeneous group of skin fragility disorders, is currently associated with mutations in as many as 21 distinct genes.
H. Vahidnezhad, L. Youssefian, A. Saeidian, J. Uitto   +3 more
semanticscholar   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, Volume 183, Issue 10, Page 2446-2463, May 2026.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology*

Anais Brasileiros de Dermatologia, 2019
Bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita are subepidermal autoimmune blistering diseases whose antigenic target is located at the basement membrane zone.
C. Santi, A. Gripp, A. Roselino, D. S. Mello, J. O. Gordilho, P. Marsillac, A. Porro   +6 more
semanticscholar   +1 more source

Progressive Linear Bullous Eruption in a Young Athlete: A Diagnostic Challenge

Journal of Paediatrics and Child Health, EarlyView.
Chon‐Wai Jeremy Chan, Matthew Verheyden, Ashwati Krishnan Varikara, Michael Chang, John Relic   +4 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source